These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33206395)

  • 1. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
    Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
    J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
    Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
    Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
    Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
    Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
    Theocharides AP; Jin L; Cheng PY; Prasolava TK; Malko AV; Ho JM; Poeppl AG; van Rooijen N; Minden MD; Danska JS; Dick JE; Wang JC
    J Exp Med; 2012 Sep; 209(10):1883-99. PubMed ID: 22945919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR3 agonism augments CD47 inhibition in acute myeloid leukemia.
    Ramsey HE; Gorska AE; Smith BN; Monteith AJ; Fuller L; Arrate MP; Savona MR
    Haematologica; 2024 Jul; 109(7):2111-2121. PubMed ID: 38152031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
    Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
    Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
    Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
    Front Immunol; 2020; 11():18. PubMed ID: 32082311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities.
    Wu F; Qiu Y; Xu Y
    Cancer Immunol Immunother; 2020 Dec; 69(12):2561-2569. PubMed ID: 32583154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 17. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
    Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
    Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
    Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
    Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.